Dual antiplatelet therapy strategies and clinical outcomes for a polymer-free biolimus A9-coated stent.

CONCLUSIONS: In a large all-comers registry, PF-BES was mostly used in HBR patients, frequently followed by very-short DAPT regimen. The reported outcomes suggest a favorable safety and efficacy profile for the PF-BES in a real-world clinical setting. (ClinicalTrials.gov identifier: NCT03622203). PMID: 31334704 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31334704?dopt=Abstract

Source: EuroIntervention - July 26, 2019 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research